title: Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals.
abstract: The effect of ginseng saponins isolated from red ginseng (a steamed and dried root of Panax ginseng) has been studied in a cyclophosphamide (CPM)-induced hyperlipidemia model in fasted rabbits. In this model, chylomicrons and very low density lipoprotein (VLDL) accumulation was known to occur as a result of reduction in lipoprotein lipase (LPL) activity in the heart and heparin-releasable heart LPL. Oral administration of ginseng saponins at a dose of 0.01 g/kg for 4 weeks was found to reverse the increase in serum triglycerides (TG) and concomitant increase in cholesterol produced by CPM treatment, especially in chylomicrons and VLDL. In addition, ginseng saponins treatment led to a recovery in postheparin plasma LPL activity and heparin-releasable heart LPL activity, which were markedly reduced by CPM treatment. In rats given 15% glycerol/15% fructose solution, postheparin plasma LPL activity declined to two third of normal rats, whereas ginseng saponins reversed it to normal levels. In the present study we first demonstrated that ginseng saponins sustained LPL activity at a normal level or protected LPL activity from being decreased by several factors, resulting in the decrease of serum TG and cholesterol.
authors.affiliation: Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Nagoya City University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: C Z
authors.initials: CZ
authors.lastname: Wu
authors.forename: D Q
authors.initials: DQ
authors.lastname: Dou
authors.forename: Y J
authors.initials: YJ
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Ogihara
mesh_terms: D000284:Administration, Oral; D000818:Animals; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D004195:Disease Models, Animal; D004789:Enzyme Activation / Q000187:drug effects; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008071:Lipoprotein Lipase / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D005894:Panax; D018517:Plant Roots; D010946:Plants, Medicinal; D011817:Rabbits; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000008:administration & dosage / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
chemical_list: D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D002914:Chylomicrons; D000960:Hypolipidemic Agents; D012503:Saponins; D014280:Triglycerides; D008071:Lipoprotein Lipase